HC Wainwright assumed coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a research report sent to investors on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $158.00 target price on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on TSRO. Cowen and Company cut their target price on TESARO from $145.00 to $124.00 and set a market perform rating for the company in a research report on Monday, June 19th. Bank of America Corporation reiterated a buy rating and set a $154.00 target price on shares of TESARO in a research report on Tuesday, June 20th. Wells Fargo & Company reiterated an outperform rating and set a $236.00 target price on shares of TESARO in a research report on Tuesday, June 20th. Leerink Swann cut their target price on TESARO from $164.00 to $143.00 and set a market perform rating for the company in a research report on Tuesday, June 20th. Finally, Raymond James Financial, Inc. reiterated a market perform rating on shares of TESARO in a research report on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. TESARO presently has a consensus rating of Buy and an average price target of $170.19.

TESARO (NASDAQ:TSRO) opened at 123.00 on Thursday. The firm’s 50-day moving average price is $122.08 and its 200 day moving average price is $133.90. TESARO has a 1-year low of $106.64 and a 1-year high of $192.94. The firm’s market capitalization is $6.66 billion.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business’s revenue for the quarter was down 17.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.28) earnings per share. On average, analysts predict that TESARO will post ($8.63) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/15/tesaro-inc-tsro-earns-buy-rating-from-analysts-at-hc-wainwright.html.

In other news, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total value of $70,211.20. Following the completion of the sale, the senior vice president now owns 6,943 shares of the company’s stock, valued at $823,439.80. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Edward C. English sold 10,862 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the sale, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last three months, insiders sold 35,692 shares of company stock valued at $4,628,976. Insiders own 40.50% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Achmea Investment Management B.V. acquired a new stake in shares of TESARO in the second quarter valued at about $234,000. Public Employees Retirement System of Ohio increased its stake in shares of TESARO by 82.4% in the second quarter. Public Employees Retirement System of Ohio now owns 36,667 shares of the biopharmaceutical company’s stock valued at $5,128,000 after buying an additional 16,569 shares during the period. Intellectus Partners LLC increased its stake in shares of TESARO by 17.7% in the second quarter. Intellectus Partners LLC now owns 6,310 shares of the biopharmaceutical company’s stock valued at $883,000 after buying an additional 950 shares during the period. California State Teachers Retirement System increased its stake in shares of TESARO by 20.8% in the second quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock valued at $9,523,000 after buying an additional 11,706 shares during the period. Finally, Cubist Systematic Strategies LLC increased its stake in shares of TESARO by 291.7% in the second quarter. Cubist Systematic Strategies LLC now owns 7,105 shares of the biopharmaceutical company’s stock valued at $994,000 after buying an additional 5,291 shares during the period.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.